+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Dermatological Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4591283
  • Report
  • March 2019
  • Region: Global
  • 114 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • AGI Dermatics
  • Allergan Inc
  • Amgen Inc.
  • Dermik Laboratories Inc.
  • Eisai Inc.
  • Genentech Inc.
  • MORE
Market Overview

The dermatological therapeutics market is expected to register a CAGR of 7%, during the forecast period.

With rising number of elderly population, dermatology care is likely to receive particular attention. As people age, their risk of developing skin-related disorders increase, due to factors, such as changes in the connective tissue, reduction in the skin's strength and elasticity, and reduction in secretions from sebaceous glands. The increasing incidence of dermatological diseases and increasing levels of awareness-related disease progression, etiology, and available therapies are leading to high growth of dermatological therapeutics.

Scope of the Report

The dermatological therapeutics market is segmented on the basis of application, drug class, and geography. By application, the market is segmented into alopecia, herpes, psoriasis, rosacea, atopic dermatitis, acne vulgaris, and other applications. By drug class, the market is segmented into anti-infectives, corticosteroids, anti-acne, calcineurin inhibitors, retinoids, and other drug classes.

Key Market Trends

By Application, the Acne Vulgaris Segment is the Largest segment, and the Atopic Dermatitis Segment is Expected to Register Robust Growth

Acne therapeutics is the largest market segment of the dermatological diagnostics market, accounting for nearly 30% of the total revenue. The high prevalence rates of acne, coupled with the availability of over-the-counter therapeutics, leads to large market size. According to the Global Burden of Disease (GBD) study, acne vulgaris affects nearly 85% of young adults aged between 12–25 years.

Atopic dermatitis is a widespread chronic inflammatory skin condition that can affect patients of all ages, and is the result of multiple environmental, immunological, genetic, and pharmacologic factors. The disease mostly flares up when the patient is around the things that cause allergic reactions. The malfunctioning in the immune system of the human body, due to asthma, is also a major causes for atopic dermatitis. Due to several lifestyle factors, the global burden of atopic dermatitis is increasing rapidly, which is, in turn, fueling the growth of the segment.

North America Dominates the Market, in Terms of Revenue, and Asia-Pacific is Expected to Register Rapid Growth

North America is expected to lead the global market. Increasing healthcare expenditure, awareness about skin diseases, and strong presence of pharmaceutical companies are anticipated to drive the growth of the market in North America. In the Asia-Pacific region, the ever-increasing pool of the patient population, increasing awareness, and increasing disposable incomes are expected to be pivotal to the robust market growth in the region.

Competitive Landscape

Many new players are emerging in this market, as a result of a number of growth opportunities. Forthcoming patent expiries of major drugs are leading to increased competition, and is further driving the market, especially in the generic sector. The overall dermatological diagnostics and therapeutics industry is forecast to witness tremendous growth, with several generic players controlling significant market share in the developing regions.

Market Overview
Note: Product cover images may vary from those shown
2 of 4


  • AGI Dermatics
  • Allergan Inc
  • Amgen Inc.
  • Dermik Laboratories Inc.
  • Eisai Inc.
  • Genentech Inc.
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Incidence Rates of Dermatology Diseases
4.2.2 Increase in Awareness Levels of Disease Progression and Etiology
4.2.3 Increase in the Elderly Population
4.3 Market Restraints
4.3.1 Serious Side Effects for Certain Classes of Therapeutic Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Application
5.1.1 Alopecia
5.1.2 Herpes
5.1.3 Psoriasis
5.1.4 Rosacea
5.1.5 Atopic Dermatitis
5.1.6 Acne Vulgaris
5.1.7 Other Applications
5.2 By Drug Class
5.2.1 Anti-infectives
5.2.2 Corticosteroids
5.2.3 Anti-acne
5.2.4 Calcineurin Inhibitors
5.2.5 Retinoids
5.2.6 Other Drug Classes
5.3 Geography
5.3.1 North America US Canada Mexico
5.3.2 Europe Germany UK France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AGI Dermatics
6.1.2 Allergan Inc
6.1.3 Amgen Inc.
6.1.4 Chester Valley Pharmaceuticals Inc.
6.1.5 Dermik Laboratories Inc.
6.1.6 Eisai Inc.
6.1.7 Ferndale Laboratories Inc.
6.1.8 Genentech Inc.
6.1.9 Medicis Pharmaceutical Corp. (Bausch Health)
6.1.10 Onset Therapeutics

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • AGI Dermatics
  • Allergan Inc
  • Amgen Inc.
  • Chester Valley Pharmaceuticals Inc.
  • Dermik Laboratories Inc.
  • Eisai Inc.
  • Ferndale Laboratories Inc.
  • Genentech Inc.
  • Medicis Pharmaceutical Corp. (Bausch Health)
  • Onset Therapeutics
Note: Product cover images may vary from those shown